CONTROL BIONICS®

BELL POTTER HEALTHCARE CONFERENCE 2026

Empowerment through proven neurotechnology

Business update, growth strategy and near-term catalysts

18 November 2026 | ASX: CBL

Jeremy Steele, CEO & Managing Director · jsteele@controlbionics.com

IMPORTANT NOTICE

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group. The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group.

Forward-looking statements. This presentation contains forward-looking statements, including statements regarding FY27 revenue, partner onboarding, trial conversions and product release timing. They are based on current expectations and assumptions and are subject to known and unknown risks, many outside the Company's control. Actual results may differ materially. Subject to its continuing obligations under the ASX Listing Rules, Control Bionics disclaims any obligation to update any forward-looking statement.

Trials, clinical and market information. Trial and pilot agreements referred to in this presentation are evaluation arrangements which, unless otherwise stated, involve no committed minimum revenue and may not convert into commercial agreements. Organisations named include paying customers, trial participants and research partners. Clinical information referred to is interim, single-centre and observational, has not been peer reviewed and does not establish therapeutic efficacy. Market size figures are management estimates. Financial information for FY27 is unaudited.

CONTROL BIONICS AT A GLANCE

One neural-signal platform. Three commercial pillars.

Non-invasive surface EMG (sEMG) that reads the faintest muscle signal, refined over 25 years with people who can barely move.



NeuroNode

PILLAR 1 · REVENUE ENGINE

Assistive Communication

NeuroNode and iOS speech devices for people with ALS/MND, cerebral palsy and spinal injury, sold through the largest AAC distributors into funded markets.



NeuroStrip

PILLAR 2 · GROWTH ENGINE

NeuroTech Solutions

NeuroStrip wearable sEMG and NeuroStrip.IQ software for rehabilitation clinics, elite sport and research. Customers buy hardware and a subscription.



Live sEMG data

PILLAR 3 · LONG-TERM OPTION

Platform & Medical Technology

Data, full-spectrum telemetry, APIs, Apple BCI and research partnerships that make the platform an asset in its own right.

25+ years of sEMG R&D, more than $40m invested

7 patent families across hardware, software and signal processing

4 funded NeuroNode markets: US, Germany, UK and Australia

+50% FY27 revenue growth target on FY26

Funded devices, sold through the largest AAC distributors

Growth scales with the number of partner consultants we train, not with Control Bionics sales headcount.

US$1B+
global AAC market, growing >10% a year. Our share is below 1%

US$4,300
NeuroNode funded under its own US reimbursement (HCPCS) code

80%+
wholesale EBITDA margin on NeuroNode

~1 quarter
from training a partner consultant to their first funded sale

Tobii Dynavox #1 global AAC provider	US rollout extended to additional states. Distribution agreement for Germany signed September 2026. US wide agreement pending
PRC-Saltillo #2 US AAC provider	US distribution agreement in place. Consultants are trained in groups, with more onboarding through FY27.
NextLevel OMNI iOS speech device	Medicare PDAC code secured 27 August 2026. Shipping since September at ~US$3,000 wholesale.
Europe Germany and UK	Germany: HMV listed March 2026, launched with Tobii Dynavox. UK: NeuroNode funded through the NHS.


NeuroNode


Speech device software

Leading sport and rehab organisations use NeuroStrip

Objective muscle data for return-to-play and rehabilitation decisions, in a >$4.2B addressable market (management estimate).



NeuroStrip IQ: live sEMG across four channels



NeuroStrip in a rehabilitation session

NEUROSTRIP

4 g
with electrode patch

4 channels
sEMG, plus motion data and video capture

0.2 µV
internal noise

3 mm
thin, worn in movement

Registered: US FDA · UK MHRA · EU MDR

ELITE SPORT

Hawthorn · GWS GIANTS · Port Adelaide · Rugby Australia · NZ Warriors · Western Force · Kansas City Chiefs · British Olympic team / University of Nottingham · UK Sports Institute · a leading European football club

REHABILITATION & CLINICAL

Mountain Land Physical Therapy (US) · Royal Rehab · Better Rehab · Rocky Bay · Meliora Medical (UK) · Mayo Clinic · Barrow Neurological Institute · STROKE LAB (Japan)

RESEARCH

Ohio University · University of Melbourne · University of Sydney · Victoria University · Mayo Clinic

Trial customers are becoming long-term paying customers

A paying customer buys NeuroStrip hardware, a NeuroStrip.IQ subscription and patches: $5k to $50k a year per organisation.

~80	organisations engaged in AU/NZ, the US and Europe	~30	in live trials	5	paying customers	0	trials ended without converting

CUSTOMER SESSIONS PER QUARTER



282 sessions in Q1 FY27, five times the March quarter. Customer organisations only; internal, demo and test use excluded.

HOW TRIALS BECOME RECURRING REVENUE

1. **Rehabilitation leads**
   Clinics record ~90 minutes of sessions against ~20 for sports clubs. re/Compete, our first repeatable rehab program, launched in November.
2. **Sport buys a service**
   Providing elite teams with access to insight not currently available
3. **Simple to buy**
   Standard hardware and NeuroStrip.IQ subscription contracts. Patches sold direct.

Six catalysts we will report against in FY27

Each ties to a milestone set out at the AGM on 13 October 2026.

WHY CONTROL BIONICS

- **Proven and protected**
  25 years of sEMG R&D, seven patent families and an FDA-cleared NeuroNode with its own US reimbursement code.
- **A funded revenue engine**
  Reimbursed devices sold by the two largest AAC distributors, at 80%+ wholesale EBITDA margin on NeuroNode.
- **A growth engine in large markets**
  NeuroStrip is used by leading sport, rehab and research organisations, and trials are converting to paid.
- **Funded to breakeven**
  $9.75m raised June–July 2026. No further capital raise is forecast before the business reaches cash breakeven.

1	**NeuroStrip conversions** First trial-cohort conversion outcomes reported	Dec quarter
2	**Elite sport** Continued club engagement. Performance use cases promoted	From Dec 2026
3	**Apple BCI** General release with the new NeuroNode Controller App	Early 2027
4	**Wholesale revenue** Becomes the largest share of Control Bionics revenue	Dec quarter
5	**Partner volume** OMNI and NeuroNode volumes ramp as more partner consultants are trained	Through FY27
6	**FY27 revenue** +50% growth on FY26 revenue of $4.77m	FY27